Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Common Equity (2016 - 2025)

ProQR Therapeutics' Common Equity history spans 6 years, with the latest figure at $57.5 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 39.27% to $57.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.5 million, a 39.27% decrease, with the full-year FY2025 number at $57.5 million, down 39.27% from a year prior.
  • Common Equity hit $57.5 million in Q4 2025 for ProQR Therapeutics, down from $94.6 million in the prior quarter.
  • Over the last five years, Common Equity for PRQR hit a ceiling of $151.0 million in Q3 2021 and a floor of $59322.7 in Q1 2021.
  • Historically, Common Equity has averaged $80.5 million across 5 years, with a median of $66.6 million in 2022.
  • The widest YoY moves for Common Equity: up 189502.52% in 2022, down 56.9% in 2022.
  • Tracing PRQR's Common Equity over 5 years: stood at $130.5 million in 2021, then plummeted by 47.88% to $68.0 million in 2022, then crashed by 34.54% to $44.5 million in 2023, then skyrocketed by 112.5% to $94.6 million in 2024, then tumbled by 39.27% to $57.5 million in 2025.
  • Business Quant data shows Common Equity for PRQR at $57.5 million in Q4 2025, $94.6 million in Q4 2024, and $44.5 million in Q4 2023.